Researchers at UT Southwestern Medical Center and the University of Alabama at Birmingham have identified a drug sequencing strategy that made the most common and deadly primary brain tumor in adults dramatically more sensitive to chemotherapy in laboratory and mouse models, providing a potential explanation for why prior clinical trials combining the same drugs failed and pointing toward a different approach that has not yet been tested in patients.
The findings, published July 8, 2026, in Science Translational Medicine, show that pretreating glioblastoma with a class of drugs called EGFR inhibitors, before rather than alongside the chemotherapy drug temozolomide (TMZ), dramatically reduced tumor cells' ability to resist the chemotherapy.
Why This Matters
Glioblastoma is the most common primary brain cancer in adults, and one of the most uniformly fatal. The standard treatment has not meaningfully changed in two decades: surgery, radiation, and temozolomide. Median survival remains approximately 15 months from diagnosis. A disease that affects roughly 14,000 Americans per year, that strikes people across all demographics, and that has resisted virtually every major therapeutic approach tested against it, represents one of the most urgent unmet needs in oncology.
"Glioblastoma is a devastating brain cancer with a dismal prognosis and no truly effective treatments. Our study could give new hope to the approximately 250,000 patients worldwide diagnosed with this disease each year," said Dr. Amyn Habib, professor of neurology and neurological surgery at UT Southwestern and staff physician at the Dallas Veterans Affairs Medical Center, according to the UT Southwestern newsroom.
What We Know So Far
The study, led by Dr. Habib's team at UT Southwestern and co-led with researchers at the University of Alabama at Birmingham, focused on a protein called MGMT (O6-methylguanine-DNA methyltransferase) that has long been recognized as one of glioblastoma's primary mechanisms of resistance to temozolomide. MGMT is a DNA repair enzyme that effectively reverses the damage TMZ causes to cancer cells, allowing them to survive chemotherapy.
The research found that EGFR (epidermal growth factor receptor) signaling in glioblastoma cells drives up MGMT production. When an EGFR inhibitor was applied first, it shut down EGFR signaling and reduced MGMT levels, leaving the tumor cells less able to repair TMZ-induced DNA damage. When temozolomide was then delivered, the tumor cells with suppressed MGMT were dramatically more sensitive to it.
Critically, the order of administration mattered. When EGFR inhibitors and temozolomide were delivered simultaneously, no sensitization effect was seen. Only the sequential approach, with the EGFR inhibitor given first to suppress MGMT, followed by TMZ, produced the benefit.
This finding has direct implications for interpreting the failure of prior clinical trials. "When the researchers examined glioblastoma samples from patients who participated in one such trial, they found that the tumor cells had high levels of MGMT that prevented TMZ from working," the UT Southwestern newsroom reported. The trials that failed gave both drugs at the same time, meaning the MGMT suppression window from EGFR inhibition was never opened before chemotherapy was delivered.
The researchers tested the EGFR inhibitor afatinib, a drug already approved for lung cancer, and found it also sensitized glioblastoma cells and mouse tumor models to TMZ, even when the tumor had already developed TMZ resistance.
Where This Research Stands in the Clinical Pathway
This is preclinical research: studies in glioblastoma cell lines and mouse models. It does not establish that this strategy works in human glioblastoma patients, and no clinical trial based on these specific findings has yet launched. The translation from mouse tumor model to human clinical efficacy is a step that many promising glioblastoma strategies have failed to make. Readers, patients, and families should understand clearly what this study represents and what it does not.
The EGFR inhibitor afatinib tested in this study is already FDA-approved for non-small cell lung cancer with EGFR mutations, which means a formal clinical trial evaluating the sequential strategy in glioblastoma patients could in principle be designed without waiting for a new drug approval. Whether and when such a trial launches is not yet announced.
What Doctors and Experts Say
Dr. Habib expressed measured optimism about the clinical implications. "If future clinical trials confirm that treatment with EGFR inhibitors sensitizes glioblastoma patients to TMZ, this strategy could eventually become the gold standard for treating this cancer," he said, according to the UT Southwestern newsroom. His framing was appropriately conditional: this requires human trial confirmation before it changes clinical practice.
The research was funded by grants from the National Institutes of Health (R01CA299152-01 and 1R01NS119225-01A1) and the National Cancer Institute Cancer Center Support Grant (P30CA142543), providing institutional backing from major federal research funders.
What the Evidence Shows and What It Does Not
MedicalDaily Evidence Check
- Study type: Preclinical research in glioblastoma cell lines and mouse tumor models
- Published in: Science Translational Medicine (doi: 10.1126/scitranslmed.adx8398), July 8, 2026
- Institution: UT Southwestern Medical Center and University of Alabama at Birmingham
- Lead researcher: Dr. Amyn Habib, Professor of Neurology and Neurological Surgery, UT Southwestern
- Key finding: Sequential pretreatment with an EGFR inhibitor (afatinib) before temozolomide reduced MGMT levels in glioblastoma cells and mouse models, sensitizing the tumors to chemotherapy
- Critical sequencing note: Simultaneous delivery of EGFR inhibitor and TMZ did not work; pretreatment was essential
- What it does not prove: That this strategy works in human patients; no human clinical trial has yet tested this specific sequential approach
- Why prior trials failed: Prior clinical trials combined EGFR inhibitors and TMZ simultaneously, which this research suggests explains why they showed no benefit
- Funding: National Institutes of Health; no pharmaceutical industry funding disclosed in available reporting
- What readers should know: This is early-stage preclinical research. Patients with glioblastoma should not change their treatment based on this finding. Speak with your neuro-oncologist about current standard of care and any clinical trials for which you may be eligible.
Who Should Pay Attention?
This research is most relevant to:
- Patients currently living with glioblastoma and their families, who deserve accurate context about the state of brain cancer research
- Neuro-oncologists and oncology researchers who follow developments in glioblastoma biology and treatment strategy
- Clinical trial teams who may design human trials based on this finding
- People who have participated in prior glioblastoma trials that tested EGFR inhibitors and temozolomide together and whose tumors did not respond
For patients currently undergoing treatment, this research does not change standard of care today.
Symptoms and Warning Signs of Glioblastoma
Glioblastoma symptoms arise when the tumor creates pressure on specific areas of the brain. Common presentations include:
- New or worsening headaches, often worse in the morning or when bending forward
- Seizures, especially new-onset seizures in adults
- Weakness or numbness in an arm, leg, or one side of the face
- Speech difficulties, including trouble finding words or understanding language
- Vision changes, including double vision or loss of peripheral vision
- Cognitive changes, including memory problems, confusion, or personality shifts
- Nausea and vomiting without a clear cause
These symptoms overlap with many other conditions. Only imaging (MRI or CT scan) and biopsy can diagnose glioblastoma. Anyone experiencing new neurological symptoms should seek prompt medical evaluation.
What You Can Do Now
- Patients currently diagnosed with glioblastoma should speak with their neuro-oncologist about clinical trial eligibility. ClinicalTrials.gov lists active trials that may include experimental approaches beyond current standard of care.
- Patient advocacy organizations including the National Brain Tumor Society maintain resources on current treatment options, clinical trials, and support for patients and families.
- Do not attempt to obtain or use EGFR inhibitors off-label for glioblastoma based on this study. These drugs are approved for lung cancer, not glioblastoma, and self-treatment outside of a supervised trial carries serious risks.
- If you are a physician or researcher interested in the translational implications of this finding, the full study is published open-access at Science Translational Medicine .
Cost and Access: What Patients Should Know
Current standard-of-care treatment for glioblastoma, including surgery, radiation, and temozolomide, is covered by Medicare, Medicaid, and most private insurance plans. Participation in clinical trials may provide access to experimental treatments at no or reduced cost to participants. Patients should ask their oncologist's office about trial navigator resources, which can help identify and enroll in relevant studies.
What Happens Next
The logical next step from this research is the design of a human Phase 1 or Phase 2 clinical trial testing sequential afatinib followed by temozolomide in newly diagnosed or recurrent glioblastoma patients. No such trial has been announced as of July 20, 2026. The researchers acknowledged that confirming this approach in human patients will require careful clinical trial design, patient stratification, and sufficient follow-up. MedicalDaily will report on any clinical trial announcement related to this finding.
The Bottom Line
UT Southwestern and UAB researchers have found a potential explanation for why prior glioblastoma trials combining EGFR inhibitors with chemotherapy failed, and have identified a sequential approach that works in laboratory and animal models. If the finding translates to human trials, it could open a new combination treatment strategy for a disease that has seen almost no survival improvement in two decades. The research is preclinical; this is not a treatment available today. It is a scientifically credible lead that the brain cancer field should move to test in patients as quickly as rigorous trial design allows.
